Literature DB >> 7477580

[Increase of degree of vaccination against influenza in at-risk patients by directed primary care invitation].

W Davidse1, R J Perenboom.   

Abstract

OBJECTIVE: To increase the coverage of influenza vaccination by a programmatic approach in a large population, aimed at the general practitioners (GPs).
DESIGN: Intervention study (prospective).
SETTING: The region of central Brabant (Tilburg and some surrounding communities), the Netherlands.
METHOD: The intervention was carried out in a population of 133,000 people (registered at 42 offices of 56 GPs, and at 27 pharmacies). Medication data from pharmacists were used for the selection of patients at risk by the GPs.
RESULTS: About 15,000 patients were selected by the GPs and invited for vaccination. The (final) coverage was 75.5% in 1993, a 56% increase over 1992. The increase in the group of comparable but non-participating GPs was 18%, in the Netherlands as a whole it was 8%.
CONCLUSION: It is quite possible to achieve a considerable increase of the coverage of influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477580

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  4 in total

1.  Influenza in The Netherlands.

Authors:  J A Knottnerus
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 2.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 3.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30

4.  "It's easier in pharmacy": why some patients prefer to pay for flu jabs rather than use the National Health Service.

Authors:  Claire Anderson; Tracey Thornley
Journal:  BMC Health Serv Res       Date:  2014-01-24       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.